Deal Discussions Distract From Disappointing Obesity Drug Sales

In this video, health-care analyst David Williamson looks at Vivus' first-quarter results and breaks it down into key takeaways for investors in both Vivus and its competitor Arena. Watch and find out why shares of the obesity-drug maker went up despite missing sales estimates and what it means now that Arena has received DEA scheduling.

Who will win the obesity drug market?
Can Vivus pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on Vivus and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and Vivus -- complete with a full year of free updates -- today.

The article Deal Discussions Distract From Disappointing Obesity Drug Sales originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.